key: cord-0939486-8yid4s33 authors: Poizeau, Florence; Oger, Emmanuel; Barbarot, Sébastien; Le Corre, Yannick; Samimi, Mahtab; Brenaut, Emilie; Aubert, Hélène; Chambrelan, Estel; Droitcourt, Catherine; Gissot, Valérie; Heslan, Christopher; Laurent, Claire; Martin, Ludovic; Misery, Laurent; Tattevin, Pierre; Toubel, Alexis; Thibault, Vincent; Dupuy, Alain title: Chilblains during lockdown are associated with household exposure to SARS-CoV-2. A multicentre case-control study date: 2021-10-04 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2021.09.032 sha: f4d88c090d189f11f07856e7e37541df1f0c7daf doc_id: 939486 cord_uid: 8yid4s33 OBJECTIVES: During the COVID-19 pandemic, numerous cases of chilblains have been reported. However, in most cases, RT-PCR or serology did not confirm SARS-CoV-2 infection. Hypotheses have been raised about an interferon-mediated immunological response to SARS-CoV-2, leading to effective clearance of the SARS-CoV-2 without the involvement of humoral immunity. Our objective was to explore the association between chilblains and exposure to SARS-CoV-2. METHODS: In this multicentre case-control study, cases were the 102 individuals referred to 5 referral hospitals for chilblains occurring during the first lockdown (March to May 2020). Controls were recruited from healthy volunteers’ files held by the same hospitals. All members of their households were included, resulting in 77 case households (262 individuals) and 74 control households (230 individuals). Household exposure to SARS-CoV-2 during the first lockdown was categorized as high, intermediate or low, using a pre-established algorithm based on individual data on symptoms, high-risk contacts, activities outside the home and RT-PCR testing. Participants were offered a SARS-CoV-2 serological test. RESULTS: After adjustment for age, the association between chilblains and viral exposure was estimated at OR=3.3, 95%CI (1.4-7.3) for an intermediate household exposure, and 6.9 (2.5-19.5) for a high household exposure to SARS-CoV-2. Out of 57 case households tested, 6 (11%) had positive serology for SARS-CoV-2, whereas all control households tested (n=50) were seronegative (p=0.03). The effect of potential misclassification on exposure has been assessed in a bias analysis. CONCLUSIONS: This case-control study demonstrates the association between chilblains occurring during the lockdown and household exposure to SARS-CoV-2. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT04455308. In the early months of the COVID-19 pandemic, the emergence of acral lesions, similar to 54 classic chilblains, have been reported worldwide [1] [2] [3] [4] [5] [6] [7] [8] [9] . As an outbreak of chilblains is 55 extremely unusual, especially during the spring season and in areas with a mild climate, they 56 were rapidly attributed to COVID-19 under the term "COVID toes" [1, 2, 4, 10] . However, the 57 association between SARS-CoV-2 and chilblains could not be ascertained, due to negative 58 tests for SARS-CoV-2 infection, whether direct (RT-PCR) or indirect (serology), in the large 59 majority of patients with chilblains. Instead, non-viral hypotheses arose: lifestyle changes 60 associated with community lockdown (changes in physical activity, unsuitable footwear, etc.) 61 [3, 9, [11] [12] [13] [14] [15] , or a surveillance bias during this anxiogenic pandemic [3] . 62 Several hypotheses have been raised regarding an immunological rationale for SARS-CoV-2 63 as a trigger for chilblains. Some researchers have suggested that chilblains could result from 64 a strong interferon response, as seen in genetic interferonopathies. The interferon response 65 could lead to rapid clearance of SARS-CoV-2, without the involvement of humoral immunity, 66 explaining the negative SARS-CoV-2 serology in most patients [8, [16] [17] [18] . 67 To address the controversy, we conducted a multicentre case-control study in Western 68 France to estimate the association between chilblains occurring during the first lockdown 69 (March 17, to May 11, 2020) and household exposure to SARS-CoV-2 within confined homes. 70 We used an algorithm based on self-reported features related to SARS-CoV-2 exposure 71 rather than serological tests, because the underlying pathophysiological hypothesis implies 72 low sensibility of serology to document SARS-CoV-2 exposure. Household exposure to SARS-CoV-2 was assessed by processing information from each 108 household member, using an algorithm established before data acquisition by consensus 109 between investigators (including dermatologists, a virologist (VT), an infectious disease 110 specialist (PT), and an epidemiologist (EO)). As a first step, the algorithm determined the 111 individual level of risk for each household member of promoting SARS-CoV-2 circulation at 112 home. Individual risk was classified as high if the household member had RT-PCR-proven 113 COVID-19, specific symptoms (i.e. anosmia or ageusia), or had had unprotected and 114 prolonged contact with a person diagnosed with COVID-19. Individual risk was classified as 115 intermediate in case of other symptoms (fever, asthenia, rhinitis, sore throat, cough, 116 dyspnea), other types of contact (protected or short-lived) with a person diagnosed with 117 COVID-19, or regular out-of-home activity during lockdown. Individual risk was classified as 118 low otherwise (asymptomatic household member who had no contact with a COVID-19-119 infected individual and no regular out-of-home activity). As a second step, the algorithm 120 classified household exposure to SARS-CoV-2 into 3 ordered categories, according to the 121 individual risk obtained for each household member: a household with at least one high-risk 122 The association between chilblains occurring during lockdown and household exposure to 135 SARS-CoV-2 was based on odds-ratio and 95% confidence interval (OR, 95%CI) estimation. 136 The analysis was first stratified on age, then adjusted for age. Age was divided into quartiles 137 in the main analysis, and modeled using a spline function in a sensitivity analysis. The 138 analysis was also stratified and adjusted for the number of individuals confined together. The composition of the households and the conditions of lockdown are described in Table 1 . 173 Case and control households did not differ for their main characteristics, except that they 174 were not evenly distributed across the 3 regions (all in Western France). Symptoms (fever, asthenia, rhinitis, sore throat, cough, dyspnea), and a prolonged 182 unprotected contact with an individual diagnosed with COVID-19 were significantly more 183 often reported in case households than in control households (Table 2) . All seropositive households were categorized at a high level of exposure to SARS-CoV-2 209 following our algorithm. Among the individuals with serology but excluded because they 210 were living alone (10 individuals with chilblains and 18 without), only one individual, without 211 chilblains, was positive (Table 3) . 212 In this case-control study comparing 77 case households to 74 control households, we 216 observed a strong, significant, and proportional association between chilblains occurring 217 during the lockdown and household exposure to SARS-CoV-2. This result is consistent with 218 another case-control study based on serological tests [20] . was not the main outcome in this study, these findings suggest that we selected a fairly 254 unbiased control group. 255 256 Our study has limitations. First, our main outcome was based on self-reported items. Hence, 257 exposure misclassification may have occurred. Non-differential misclassification, affecting 258 both cases and controls, may have occurred for viral symptoms that are not specific to SARS-259 CoV-2. However, these were only used to determine the intermediate level of SARS-CoV-2 260 resulted in a low incidence of other respiratory viruses. Also, past exposures may be more 262 readily recalled by cases, possibly because of repeated questioning by physicians, leading to 263 a differential misclassification. However, the odds-ratio would remain significant, even with 264 a 20% misclassification rate. False positive and false negative rates among case households, 265 control households or both were simulated in the bias analysis in Supplementary Table 2 266 [22]. Furthermore, a significant association was also observed for objective criteria not 267 subject to misclassification, such as serology results. Second, asymptomatic cases make 268 analyses of intra-household transmission unreliable, and this is the reason why we 269 considered the household as a whole for the entire duration of the lockdown. Third, residual 270 confounding is possible. For example, urban and rural living area was not specified in the 271 questionnaire and could thus not be taken into account in the analysis. Last, seropositivity 272 could have been underestimated in our study, because serologies were performed 2 to 5 273 months after the study period, and anti-nucleoprotein antibodies may wane within months 274 [23]. However, antibody waning would have affected case and control households similarly, 275 which would have led to an underestimation of the association [24, 25] . -a features of at least one individual in the household 432 b among fever, asthenia, rhinitis, sore throat, cough, dyspnea 433 c period when RT-PCR testing was restricted to hospitalized patients or health care workers. Case households Control households P-value a N=57 N=67 b N=50 N=68 b Positive serology 6 (10.5%) 6 (9.0%) 0 (0%) 1 (1.5%) 0.03 a Comparison of households included in the main analysis and who were tested for serology (57 case 436 and 50 control households), using Fisher's exact test Acral 324 cutaneous lesions in the time of COVID-19 Pernio-327 like skin lesions associated with COVID-19: A case series of 318 patients from 8 328 countries Most chilblains 330 observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing Characterization of acute acral skin lesions in 335 nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak Chilblains is 338 a common cutaneous finding during the COVID-19 pandemic: A retrospective 339 nationwide study from France Laboratory, and Interferon-Alpha Response Characteristics of Patients With 349 Chilblain-like Lesions During the COVID-19 Pandemic Evaluation of 352 Chilblains as a Manifestation of the COVID-19 Pandemic A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric 356 patients with chilblain-like lesions: lights and shadows on the relationship with COVID-357 19 infection Emerging Evidence of the Direct Association Between And Chilblains-Reply Response to "No evidence of SARS-CoV-2 361 infection by polymerase chain reaction or serology in children with pseudo-chilblain Reply from the authors Assessment of Acute Acral Lesions in a Case Series of Children 365 and Adolescents During the COVID-19 Pandemic Chilblains and COVID-19: further evidence against a 367 causal association The 372 differing pathophysiologies that underlie COVID-19-associated perniosis and 373 thrombotic retiform purpura: a case series Paraviral eruptions in the era of COVID-19: Do some skin manifestations 375 point to a natural resistance to SARS-CoV-2? When interferon tiptoes through COVID-19: Pernio-377 like lesions and their prognostic implications during SARS-CoV-2 infection Clinical characteristics, etiologic associations, laboratory 380 findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series 381 of 104 patients at Mayo Clinic Association between COVID-19 and 384 chilblains: a case-control study Estimating 386 the burden of SARS-CoV-2 in France Potential sensitivity 388 of bias analysis results to incorrect assumptions of nondifferential or differential 389 binary exposure misclassification Bias from 395 outcome misclassification in immunization schedule safety research When will nondifferential misclassification of 398 an exposure preserve the direction of a trend? Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A 401 registry-based study of 414 cases Gemelli Against COVID-19 Post-Acute Care Study Group Persistent Symptoms in Patients After Acute COVID-19 Long 405 COVID in the skin: a registry analysis of COVID-19 dermatological duration Long COVID in the Faroe Islands: A Longitudinal Study Among Nonhospitalized Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: 412 A cross-sectional study Sequelae in Adults at 6 Months After COVID-19 Infection Assessment of the Frequency and Variety of Frequency of relapse and persistent cutaneous symptoms after a first episode of 421 chilblain-like lesion during the COVID-19 pandemic The long-term 424 outcome of patients with chilblains associated with SARS-CoV-2